Nkarta doubles on promising data from cell therapies

Nkarta

25/04/2022 15:26

(Updates)
    ** Cell therapy developer's shares  NKTX.O  soar 112.7% to
$16.53, their biggest one-day rise if gains hold 
    ** Co says two of its experimental cell therapy treatments
showed promise in patients with different blood disorders
 urn:newsml:reuters.com:*:nGNX4V9ZHz
    ** Says 3 of 5 patients with acute myeloid leukemia did not
have any signs of disease after treatment with NKX101
    ** NKTX says both drugs, NKX101 and NKX019, were well
tolerated, with no reports of side effects that are associated
with CAR-T cell therapies, such as cytokine release syndrome or
graft versus host disease
    ** "We still need durability data and more (patients), but
showing these responses today, is a major plus" - Mizuho analyst
Salim Syed
    ** Including session's gains, stock down ~4% YTD, versus a
~17% slide in the Nasdaq biotech index  .NBI  in the same time
period 

 (Reporting by Manas Mishra)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))